Cooperation between endothelial cells and bone in bone remodelling is well established. In contrast, bone microvasculature supporting the growth of primary tumors and metastasis is poorly understood. Several antiangiogenic agents have recently been undergoing trials, although an extensive body of clinical data and experimental research have proved that angiogenic pathways differ in each tumor type and stage. Here, for the first time, we characterize at the molecular and functional level tumor endothelial cells from human bone sarcomas at different stages of disease and with different histotypes. We selected a CD31 + subpopulation from biopsies that displayed the capability to grow as adherent cell lines without vascular endothelial growth factor (VEGF). Our findings show the existence in human primary bone sarcomas of highly proliferative endothelial cells expressing CD31, CD44, CD105, CD146 and CD90 markers. These cells are committed to develop capillary-like structures and colony formation units, and to produce nitric oxide. We believe that a better understanding of tumor vasculature could be a valid tool for the design of an efficacious antiangiogenic therapy as adjuvant treatment of sarcomas.
References
[1]
Mundy, G.R. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2, 584–593, doi:10.1038/nrc867.
[2]
Guise, T. Examining the metastatic niche: Targeting the microenvironment. Semin. Oncol. 2010, 37, S2–S14, doi:10.1053/j.seminoncol.2010.10.007.
[3]
Potente, M.; Gerhardt, H.; Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146, 873–887, doi:10.1016/j.cell.2011.08.039.
[4]
De Nigris, F.; Schiano, C.; Infante, T.; Napoli, C. CXCR4 inhibitors: Tumor vasculature and therapeutic challenges. Recent Pat. Anticancer Drug Discov. 2012, 7, 251–264, doi:10.2174/157489212801820039.
[5]
Hanahan, D.; Coussens, L.M. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21, 309–322, doi:10.1016/j.ccr.2012.02.022.
St. Croix, B.; Rago, C.; Velculescu, V.; Traverso, G.; Romans, K.E.; Montgomery, E.; Lal, A.; Riggins, G.J.; Lengauer, C.; Vogelstein, B.; et al. Genes expressed in human tumor endothelium. Science 2000, 289, 1197–1202, doi:10.1126/science.289.5482.1197.
[8]
Bagley, R.G.; Honma, N.; Weber, W.; Boutin, P.; Rouleau, C.; Shankara, S.; Kataoka, S.; Ishida, I.; Roberts, B.L.; Teicher, B.A. Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvasc. Res. 2008, 76, 180–188, doi:10.1016/j.mvr.2008.07.008.
[9]
De Bock, K.; Cauwenberghs, S.; Carmeliet, P. Vessel abnormalization: Another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr. Opin. Genet. Dev. 2011, 21, 73–79, doi:10.1016/j.gde.2010.10.008.
[10]
Bussolati, B.; Deregibus, M.C.; Camussi, G. Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies. Curr. Vasc. Pharmacol. 2010, 8, 220–232, doi:10.2174/157016110790887036.
[11]
Di Tomaso, E.; Capen, D.; Haskell, A.; Hart, J.; Logie, J.; Jain, R.K.; McDonald, D.M.; Jones, R.; Munn, L.L. Mosaic tumor vessels: Cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res. 2005, 65, 5740–5749, doi:10.1158/0008-5472.CAN-04-4552.
[12]
Virrey, J.J.; Golden, E.B.; Sivakumar, W.; Wang, W.; Pen, L.; Sch？nthal, A.H.; Hofman, F.M.; Chen, T.C. Glioma-associated endothelial cells are chemoresistant to temozolomide. J. Neurooncol. 2009, 95, 13–22, doi:10.1007/s11060-009-9891-7.
[13]
Xiong, Y.Q.; Sun, H.C.; Zhang, W.; Zhu, X.D.; Zhuang, P.Y.; Zhang, J.B.; Wang, L.; Wu, W.Z.; Qin, L.X.; Tang, Z.Y. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin. Cancer Res. 2009, 15, 4838–4346, doi:10.1158/1078-0432.CCR-08-2780.
[14]
Bacci, G.; Longhi, A.; Versari, M.; Mercuri, M.; Briccoli, A.; Picci, P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy 15-year experience in 789 patients treated at a single institution. Cancer 2006, 106, 1154–1161, doi:10.1002/cncr.21724.
[15]
Ganjoo, K.; Jacobs, C. Antiangiogenesis agents in the treatment of soft tissue sarcomas. Cancer 2010, 116, 1177–1183, doi:10.1002/cncr.24859.
[16]
De Nigris, F.; Rossiello, R.; Schiano, C.; Arra, C.; Williams-Ignarro, S.; Barbieri, A.; Lanza, A.; Balestrieri, A.; Giuliano, M.T.; Ignarro, L.J.; et al. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. Cancer Res. 2008, 68, 1797–1808, doi:10.1158/0008-5472.CAN-07-5582.
[17]
De Nigris, F.; Crudele, V.; Giovane, A.; Casamassimi, A.; Giordano, A.; Garban, H.J.; Cacciatore, F.; Pentimalli, F.; Marquez-Garban, D.C.; Petrillo, A.; et al. CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc. Natl. Acad. Sci. USA 2010, 107, 14484–14489, doi:10.1073/pnas.1008256107.
[18]
Schiano, C.; Grimaldi, V.; Casamassimi, A.; Infante, T.; Esposito, A.; Giovane, A.; Napoli, C. Different expression of CD146 in human normal and osteosarcoma cell lines. Med. Oncol. 2012, 29, 2998–3002, doi:10.1007/s12032-012-0158-3.
[19]
McDonald, D.M.; Foss, A.J. Endothelial cells of tumor vessels: Abnormal but not absent. Cancer Metastasis Rev. 2000, 19, 109–120, doi:10.1023/A:1026529222845.
[20]
Z？ller, M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer 2011, 24, 254–267, doi:10.1038/nrc3023.
[21]
Fuchs, S.; Dohle, E.; Kolbe, M.; Kirkpatrick, C.J. Outgrowth endothelial cells: Sources, characteristics and potential applications in tissue engineering and regenerative medicine. Adv. Biochem. Eng. Biotechnol. 2010, 123, 201–217.
[22]
Kanczler, J.M.; Oreffo, R.O. Osteogenesis and angiogenesis: The potential for engineering bone. Eur. Cell Mater. 2008, 15, 100–114.
[23]
Bussolati, B.; Deambrosis, I.; Russo, S.; Deregibus, M.C.; Camussi, G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J. 2003, 17, 1159–1161.
[24]
De Bock, K.; Cauwenberghs, S.; Carmeliet, P. Vessel abnormalization: Another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr. Opin. Genet. Dev. 2011, 21, 73–79, doi:10.1016/j.gde.2010.10.008.
[25]
Fadini, G.P.; Losordo, D.; Dimmeler, S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ. Res. 2012, 110, 624–637, doi:10.1161/CIRCRESAHA.111.243386.
Tilki, D.; Hohn, H.-P.; Ergün, B.; Rafii, S.; Ergün, S. Emerging biology of vascular wall progenitor cells in health and disease. Trends Mol. Med. 2009, 15, 501–509.
[28]
Zhu, H.; Shao, Q.; Sun, X.; Deng, Z.; Yuan, X.; Yu, D.; Zhou, X.; Ding, Y. The mobilization, recruitment and contribution of bone marrow-derived endothelial progenitor cells to the tumor neovascularization occur at an early stage and throughout the entire process of hepatocellular carcinoma growth. Oncol. Rep. 2012, 28, 1217–1224.
Liu, W.; Ahmad, S.A.; Reinmuth, N.; Shaheen, R.M.; Jung, Y.D.; Fan, F.; Ellis, L.M. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 2000, 5, 323–328, doi:10.1023/A:1009679307513.
[31]
Díez, M.; Musri, M.M.; Ferrer, E.; Barberà, J.A.; Peinado, V.I. Endothelial progenitor cells undergo an endothelial-to-mesenchymal transition- like process mediated by TGFbetaRI. Cardiovasc. Res. 2010, 88, 502–511, doi:10.1093/cvr/cvq236.
[32]
Kurose, K.; Hoshaw-Woodard, S.; Adeyinka, A.; Lemeshow, S.; Watson, P.H.; Eng, C. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: Clues to tumour-microenvironment interactions. Hum. Mol. Genet. 2001, 10, 1907–1913, doi:10.1093/hmg/10.18.1907.
[33]
Akino, T.; Hida, K.; Hida, Y.; Tsuchiya, K.; Freedman, D.; Muraki, C.; Ohga, N.; Matsuda, K.; Akiyama, K.; Harabayashi, T.; et al. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am. J. Pathol. 2009, 175, 2657–2667, doi:10.2353/ajpath.2009.090202.
[34]
Secchiero, P.; Zorzet, S.; Tripodo, C.; Corallini, F.; Melloni, E.; Caruso, L.; Bosco, R.; Ingrao, S.; Zavan, B.; Zauli, G. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin’s lymphoma xenografts. PLoS One 2010, 1, e11140.
[35]
Ho, I.A.; Toh, H.C.; Ng, W.H.; Teo, Y.L.; Guo, C.M.; Hui, K.M.; Lam, P.Y. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem. Cells 2013, 31, 146–155, doi:10.1002/stem.1247.
[36]
Regan, E.R.; Aird, W.C. Dynamical systems approach to endothelial heterogeneity. Circ. Res. 2012, 111, 110–130, doi:10.1161/CIRCRESAHA.111.261701.
[37]
Resch, T.; Pircher, A.; K？hler, C.M.; Pratschke, J.; Hilbe, W. Endothelial progenitor cells: Current issues on characterization and challenging clinical applications. Stem Cell Rev. 2012, 8, 926–939, doi:10.1007/s12015-011-9332-9.
[38]
Langley, R.R.; Fidler, I.J. The seed and soil hypothesis revisited-The role of tumor stroma interactions in metastasis to different organs. Int. J. Cancer 2011, 128, 2527–2535, doi:10.1002/ijc.26031.
[39]
Amini, A.R.; Laurencin, C.T.; Nukavarapu, S.P. Differential analysis of peripheral blood- and bone marrow-derived endothelial progenitor cells for enhanced vascularization in bone tissue engineering. J. Orthop. Res. 2012, 30, 1507–1515, doi:10.1002/jor.22097.
